Core Viewpoint - Tulikivi Corporation reported a significant decline in net sales and profitability for the financial year 2025, attributed to economic uncertainty and lower demand in the construction sector, while strategic projects are progressing as planned. Financial Performance - The Tulikivi Group's net sales were EUR 29.5 million for the review period, down from EUR 33.3 million in the previous year, representing an 11.4% decrease [4] - The comparable operating profit was EUR -0.1 million, a decline from EUR 2.1 million, indicating a 105.3% decrease [4] - The operating profit for the review period was EUR -0.6 million, compared to EUR 2.1 million in the previous year, marking a 126.8% decline [4] - Profit before tax was EUR -1.3 million, down from EUR 1.4 million, reflecting a 190.1% decrease [4] - The total comprehensive income for the period was EUR -1.1 million, compared to EUR 1.2 million, a 193.6% decline [4] Operational Highlights - The equity ratio at the end of the review period was 48.6%, down from 51.9% [3] - Order books stood at EUR 2.6 million, a decrease from EUR 2.8 million [3] - The company recorded EUR 0.4 million in non-recurring expenses for the financial year, primarily related to the winding down of its Russian subsidiary [2] Market and Strategic Developments - The Suomussalmi talc project is progressing well, with key achievements including advancements in environmental permit applications and enrichment test runs [12] - The company is expanding its sales and distribution network in Central Europe, aiming to increase the number of fireplace export dealer locations from 330 to 500 by the end of 2026 [10] - The sauna business is also seeing growth, with the launch of the new Kevo electric sauna heater collection and preparations for sales in North America [11] Management Commentary - The Managing Director noted that lower net sales in the fourth quarter were due to economic uncertainty causing consumers to delay renovation and construction projects [5] - Poor profitability was attributed to lower productivity in quarrying and production, along with a slower recovery in demand for fireplaces [6]

Financial Data and Key Metrics Changes - Figma reported Q4 2025 revenue of $304 million, representing a 40% year-over-year growth rate, and full-year revenue of $1.056 billion, up 41% year-over-year [5][25] - The net dollar retention rate for customers with more than $10,000 in ARR increased by five percentage points quarter-over-quarter to 136%, marking the highest rate in the last 10 quarters [5][26] - The company ended the year with $1.7 billion in cash, cash equivalents, and marketable securities [5][32] Business Line Data and Key Metrics Changes - Figma expanded from four to eight products in 2025 and launched over 200 features, including new AI-native functionalities [5][6] - Weekly active users of Figma Make grew over 70% quarter-over-quarter, with over 50% of paid customers spending more than $100,000 in ARR using Figma Make weekly [12][25] Market Data and Key Metrics Changes - International revenue grew 45% year-over-year, with international users representing approximately 85% of monthly active users and accounting for 54% of revenue in Q4 [28][29] - The company is seeing strong expansion dynamics as customers broaden their use of the platform, with 67 paid customers spending more than $1 million in ARR, growing 68% year-over-year [27] Company Strategy and Development Direction - Figma is focused on defining new AI-native workflows and supporting customers as they adapt to new ways of working, while maintaining a disciplined approach to scaling the business [33][34] - The company aims to enhance integration between Figma Make and Figma Design, emphasizing the importance of round-tripping between code and design [61][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term cash-generating profile of the business, despite a sequential decline in adjusted free cash flow due to investments in infrastructure and AI [32][33] - For Q1 2026, Figma expects revenue in the range of $315 million to $317 million, implying 38% growth at the midpoint, and for the full year, revenue is anticipated to be between $1.366 billion and $1.374 billion, implying 30% growth at the midpoint [34] Other Important Information - Stock-based compensation was elevated in 2025 due to IPO-related expenses and is expected to improve as a percentage of revenue as the company scales [33] - The company is excited about the potential of AI to enhance creative processes and is pushing the boundaries of what can be created on the Figma platform [20][23] Q&A Session Summary Question: Insights on the impact of agentic layer offerings on UI/UX - Management believes that while agents will take on more work, humans will still need visual interfaces for understanding and auditing, which will keep design as a critical differentiator [38][39] Question: Guidance on credit consumption monetization - Management expects to refine guidance based on observed seat adoption behavior and usage trends, with 75% of paid customers consuming AI credits weekly [41][42] Question: User types and budget implications from Figma Make - Management noted an increase in non-designer roles engaging with design tasks, indicating a shift towards more generalist responsibilities within teams [65][66] Question: Concerns about AI partnerships and product development - Management emphasized the importance of maintaining control over design tasks while leveraging AI advancements, focusing on integrating AI capabilities into the product roadmap [54][71] Question: Pricing and packaging impact on revenue - Management indicated that the pricing changes implemented last year will continue to benefit revenue, with a growing impact expected as customers renew [56][57]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $724 million, representing a 2% year-over-year increase, with a 7% growth in non-respiratory revenue excluding donor screening [7][18] - Full year revenue reached $2.73 billion, achieving the company's financial guidance for 2025, with non-respiratory revenue growing 5% [7][18] - Adjusted EBITDA margin was 22%, reflecting a 240 basis point improvement over the prior year [8][22] - Adjusted diluted EPS was $0.46 in Q4 and $2.12 for the full year, indicating a 15% year-over-year growth [22] Business Line Data and Key Metrics Changes - Labs business reported a strong growth of 7% in Q4 and 6% for the full year, accounting for 55% of total company revenue [7][18] - Immunohematology business grew 3% for the full year, maintaining its leading global market position [18] - Triage business saw a revenue increase of 16% in Q4 and 7% for the full year [18] - Respiratory revenue declined 14% in Q4 and 20% for the full year due to lower COVID testing [18] Market Data and Key Metrics Changes - North America region revenue was up 4% in Q4 but down 2% for the year, excluding donor screening [20] - Europe, Middle East, and Africa showed flat growth for the quarter and 4% growth for the year, with a significant increase in Adjusted EBITDA margins by over 900 basis points [20] - Latin America experienced a 17% increase in Q4 and 18% for the year, while Japan and Asia-Pacific grew 4% in Q4 and 6% for the year [20] - China grew 5% in Q4 and 3% for the full year [21] Company Strategy and Development Direction - The company established three priorities: customer-centric operations, strengthening operational and financial performance, and accelerating product development for long-term growth [6] - The focus is on optimizing the customer experience and driving effective execution across all business dimensions [9] - The company aims to maximize value by delivering superior outcomes for customers and converting that value into attractive returns for shareholders [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong market positions and high renewal rates [35] - The company anticipates continued growth in the Labs business and is optimistic about new product launches in 2026 [14][25] - Management acknowledged challenges in cash flow conversion but emphasized ongoing efforts to improve cash flow metrics [31][88] Other Important Information - A significant non-cash goodwill impairment charge of $701 million was recorded in Q3, which does not impact cash or operations [8][22] - Joe Busky, CFO, announced his retirement effective June 2026, with a search for his successor already initiated [9][10] Q&A Session Summary Question: Free cash flow guidance and timing issues - Joe Busky explained that Q4 cash flow was lower than expected due to timing issues with accounts receivable and late revenue collection [30][31] Question: Sustainability of lab growth trends - Brian Blaser highlighted strong underlying growth rates across the business and emphasized opportunities in immunoassay and low market penetration [33][35] Question: China market updates - Management provided updates on potential nationalized value-based procurement programs but noted no new developments [40][41] Question: Gross margin performance - Joe Busky discussed factors affecting gross margins, including tariffs and product mix, and projected flat margins for 2026 [67][68] Question: Lex Diagnostics platform timeline - Jonathan Siegrist confirmed that the FDA review process for the Lex platform is progressing as planned, with no current issues [72] Question: R&D pipeline and product launches - Management indicated a focus on expanding the product portfolio and enhancing offerings in both domestic and international markets [76][78]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $724 million, representing a 2% year-over-year increase from $708 million, with a 7% growth in non-respiratory revenue excluding donor screening [7][18] - Full year revenue reached $2.73 billion, achieving the 2025 financial guidance, with non-respiratory revenue growing 5% [7][18] - Adjusted EBITDA margin was 22%, a 240 basis point improvement over the prior year [8][22] - Adjusted diluted EPS was $0.46 for Q4 and $2.12 for the full year, reflecting a 15% year-over-year growth [22] Business Line Data and Key Metrics Changes - Labs business reported a 7% growth in Q4 and 6% for the full year, representing 55% of total company revenue [7][18] - Immunohematology grew 3% for the full year, maintaining its leading global market position [18] - Triage business revenue increased by 16% in Q4 and 7% for the full year [18] - Respiratory revenue declined by 14% in Q4 and 20% for the full year due to lower COVID testing [18] Market Data and Key Metrics Changes - North America region revenue was up 4% in Q4 but down 2% for the year, excluding donor screening [20] - Europe, Middle East, and Africa (EMEA) growth was flat in Q4 and up 4% for the year, with adjusted EBITDA margins increasing by over 900 basis points [20] - Latin America saw a 17% increase in Q4 and 18% for the year, while Japan and Asia-Pacific grew 4% in Q4 and 6% for the year [20] - China grew 5% in Q4 and 3% for the full year [21] Company Strategy and Development Direction - The company established three priorities: customer-centric operations, strengthening operational and financial performance, and accelerating product development for long-term growth [6][9] - The focus is on optimizing the customer experience and driving effective execution across all business dimensions [9] - The company aims to maximize value by delivering superior outcomes for customers and converting that value into attractive returns for shareholders [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong market positions and high renewal rates [35] - The company anticipates continued growth in the Labs business and is optimistic about new product launches in 2026 [14][25] - Management acknowledged challenges in cash flow conversion but emphasized ongoing efforts to improve cash flow metrics [31][89] Other Important Information - A significant non-cash goodwill impairment charge of $701 million was recorded in Q3, which does not impact cash or operations [22] - The CFO announced plans to retire in June, with a search for a successor already initiated [9][10] Q&A Session Summary Question: Free cash flow guidance and timing issues - The CFO explained that Q4 cash flow was lower than expected due to timing issues with accounts receivable and late revenue collection [30][31] Question: Sustainability of Labs business growth - Management highlighted strong underlying growth rates and opportunities in immunoassay and underpenetrated markets as key factors for sustaining growth [35] Question: Updates on China market and VBP program - Management stated that there are no new updates on the nationalized VBP program for dry chemistry test strips, with potential impacts estimated at 0.5% to 1% of total revenue [40][41] Question: Gross margin outlook - The CFO discussed factors affecting gross margins, including tariffs and product mix, and projected flat gross margins for 2026 with potential improvements in the following years [68][70] Question: LEX Diagnostics platform timeline - Management indicated that the FDA review process for the LEX platform is progressing as planned, with no current issues [73] Question: R&D pipeline and U.S. market focus - Management confirmed that while OUS markets are a priority, there are plans to enhance the U.S. product offerings through new menu additions [77][79]

🗣️ Buildoooors, a reminder.Hydropower Fellowship Cohort 3 applications are OPEN 🫶3 months of product + growth + fundraising support Real operators, real feedback, real momentum Demo Day with VCs + warm intros for standout teamsApply 👇 https://t.co/bcpFIDF18fSui (@SuiNetwork):Applications are now open for Hydropower Fellowship Cohort 3 on Sui.A 3-month program for builders who want to take their products to the next level.If you’re building on Sui, this one’s for you 👇 https://t.co/CMtsGNtiQE ...

[प्रशंसा] गुड मॉर्निंग जीनियस गुड मॉर्निंगम जीनियस राइट यस मैम गुड मॉर्निंग एंड जीनियस गुड मॉर्निंग मैम सो आई वुड लव टू कॉल यू ऑल ऑफस आर द टू व्हाट सी एंड दे आर द ओनली वन हु कैन सर्वाइव द हार्डेस्ट ऑफ़ द एवरीबडी फियर अबाउट एआई दे नॉट नो व्हाट एक्स जॉब गोइंग टू चेंज आई नो वन थिंग फॉर शो दिस दे आर गोइंग टू रीड इन देम [प्रशंसा] सशन फॉर एवरीथिंग एवरीबडी स्टडिंग हाउ आई डू दिस हाउ आई डू दैट बट यू हैव एआई सलूशन फॉर इट एवरीबडी इन योर फैमिली मेंबर देसी समथिंग से दे वांट देयर प्रोफेशनल फोटो दे वांट देर आईडी कार्ड टू ब ...

Core Insights - FORGE is hosting the Make It Here: CT Product Development Grant Awards on January 22, 2026, to announce the latest grant recipients aimed at supporting Connecticut manufacturers and hardtech companies [1] - The FORGE Connecticut Product Development Grant program, backed by the Manufacturing Innovation Fund, assists local manufacturers in overcoming product development challenges and fostering in-state supplier relationships [2][3] - The event will feature a panel discussion on the future of regional manufacturing and guided tours of Kubtec Medical Imaging's facility [3][4] Company Overview - FORGE is a nonprofit organization that aids hardtech innovators and emerging manufacturing companies in product development and scaling production [5] - The organization has supported over 1,000 innovators and contributed to the creation of over 10,000 jobs in innovation and manufacturing sectors [6] Event Details - The Make It Here event will include a panel discussion titled "Fueling Connecticut's Emerging Manufacturers: Capital, Collaboration and the Future of Regional Manufacturing" [3] - M&T Bank is presenting the event, highlighting its commitment to supporting local manufacturers and innovators [3]

An obscure company pivoted, then pivoted again, nearly ran out of money—and built a hit product https://t.co/IukafAhGCX ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Consumer Solutions Worldwide (CSW), (Cayman) Limited 環球園藝有限公司* (Incorporated in the Cayman Islands with limited lia ...

An obscure company pivoted, then pivoted again, nearly ran out of money—and built a hit product https://t.co/W47gERee80 ...